Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
Werner Poewe, Dieter Volc, Klaus Seppi, Rossella Medori, Petra Lührs, Alexandra Kutzelnigg, Atbin Djamshidian, Caroline Thun-Hohenstein, Wassilios G Meissner, Olivier Rascol, Achim Schneeberger, Günther Staffler, Werner Poewe, Klaus Seppi, Atbin Djamshidian, Roberto deMarzi, Beatrice Heim, Stephanie Mangesius, Raphaela Stolz, Katarzyna Wachowicz, Dieter Volc, Caroline Thun-Hohenstein, Constanze Riha, Achim Schneeberger, Vera Bürger, Gergana Galabova
Journal of Parkinson's disease 2022;11(3):1079-1089